ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVLO Evelo Biosciences Inc

0.3165
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evelo Biosciences Inc NASDAQ:EVLO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.3165 0.3051 0.3114 0 01:00:00

Evelo Biosciences to Present at Upcoming Investor Conferences in June

26/05/2021 12:00pm

GlobeNewswire Inc.


Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Evelo Biosciences Charts.

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present at three upcoming virtual investor conferences in June:

Jefferies Virtual Healthcare Conference. Management will host a presentation at 1:30 p.m. ET on Wednesday, June 2, 2021.

JMP Securities Life Sciences Conference. Management will host a fireside chat at 1:00 p.m. ET on Wednesday, June 16, 2021.

Raymond James Human Health Innovation Conference. Management will host a presentation at 9:20 a.m. ET on Tuesday, June 22, 2021.

Live audio webcasts of the presentations will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of these webcasts will be available for approximately 30 days following each presentation.

About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX™, the small intestinal axis, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

ContactJessica Cotrone, 978-760-5622jcotrone@evelobio.com

1 Year Evelo Biosciences Chart

1 Year Evelo Biosciences Chart

1 Month Evelo Biosciences Chart

1 Month Evelo Biosciences Chart

Your Recent History

Delayed Upgrade Clock